# V. Mapping  Competitive landscape Perplexity.docx

V. Mapping the Competitive Landscape – Comprehensive Edition

The animal nutraceutical market is consolidating around a vertically integrated set of players spanning pharmaceutical, feed additive, and consumer health channels. Scale, clinical differentiation, and margin characteristics vary sharply between pet-focused and livestock-oriented assets, driving distinct valuation outcomes.investor.zoetis+2​



V.1 Key Players and Portfolio Architecture

V.1.1 Pharma-linked animal health groups

The intersection of pharmaceutical R&D capability with animal-health distribution is reshaping the competitive structure. These players increasingly offer a "continuum of care" spanning therapeutic drugs, vaccines, parasiticides, and functional supplements and nutraceuticals aimed at veterinarians, pet owners, and livestock producers seeking preventive and performance-enhancing solutions.

Major players:

Zoetis Inc. (USA). The world's largest animal health company, Zoetis generated approximately USD 9.3 billion in 2024 revenue, with strong operational growth of 11%. The company operates across companion animal (dogs, cats, equine) and livestock (cattle, swine, poultry, fish) segments. In late 2024, Zoetis divested its medicated feed additive portfolio to Phibro for USD 350 million, strategically focusing on vaccines, biologics, and genetic programs while maintaining a growing nutraceutical and supplement portfolio in companion animals.investor.zoetis+2​

Merck Animal Health (USA). A division of Merck & Co., with USD 5.9 billion in 2024 sales (up 4% reported, 8% constant currency). Merck Animal Health operates across livestock and companion animals, with key franchises including BRAVECTO (parasiticide, USD 1.1 billion annual sales) and expanded presence in aquaculture following the July 2024 acquisition of Elanco's aqua business.finance.yahoo+2​

Boehringer Ingelheim Animal Health (Germany). With approximately EUR 4.7 billion (USD 5.0 billion equivalent) in 2024 animal health revenue, Boehringer is a major player in livestock vaccines, companion-animal parasiticides (NexGard portfolio), and therapeutic innovation. Recent launches include SENVELGO (oral diabetes treatment for cats) and NexGard PLUS (oral parasiticide combo for dogs), with strong momentum in poultry and ruminant segments.boehringer-ingelheim+1​

Phibro Animal Health (USA). A specialized animal-health producer that acquired Zoetis' medicated feed additive portfolio (approximately USD 1.4 billion on a last-twelve-months basis post-acquisition, October 2024). Phibro focuses on production-animal health, specialty feed additives, and increasingly companion-animal supplements.news.zoetis+1​

Elanco Animal Health (USA). A mid-sized global player with USD 4.4 billion in 2024 revenue (flat reported, 3% organic constant currency growth). Elanco operates across pet health (USD 2.1 billion, 48% of revenue) and farm animal (USD 2.3 billion, 51% of revenue) with key innovation products including Zenrelia (JAK inhibitor for dogs), Credelio Plus (oral parasiticide), and Experior (livestock antimicrobial alternative).investor.elanco+1​

Ceva Santé Animale (France). A privately held, French-based company with approximately EUR 1.77 billion (USD 1.91 billion) in 2024 revenue and strong valuation momentum (recently valued at EUR 9.2 billion in a new funding round). Ceva operates across 47 countries with a focus on innovation in vaccines, particularly nucleotide vaccines for companion animals, and preventive medicine solutions.reuters+2​

Vetoquinol (France). A publicly traded veterinary pharmaceutical company with EUR 539 million (USD 580 million equivalent) in 2024 sales, up 2.2% at constant exchange rates. Vetoquinol focuses on "Essential" products (nutraceuticals and companion-animal therapeutics) which now represent 61% of sales and are growing at >8% annually, with strong margins and a strategic shift toward preventive and functional nutrition.finance.yahoo+1​

Other significant players: Eli Lilly (legacy animal health operations), regional veterinary pharmaceutical producers in Europe, Asia, and Latin America increasingly adding nutraceutical portfolios as core antibiotics commoditize.



V.1.2 Feed and specialty nutrition majors (livestock-primary)

These companies form the production backbone for industrial livestock and aquaculture, combining commodity-scale feed operations with increasingly science-driven additives and microbial-technology platforms. Their nutraceuticals—probiotics, enzymes, organic acids, phytogenics, minerals, yeast derivatives, amino acids—are embedded into premixes and complete feeds and serve as critical alternatives to antibiotic growth promoters post-AGP/ZnO restrictions.

Major players:

DSM-Firmenich – Animal Nutrition & Health (ANH) division (Netherlands/Switzerland). The ANH business generated approximately EUR 3.32 billion in 2024 sales and roughly EUR 343 million of adjusted EBITDA, representing a 10.3% margin. Performance has been supported by normalizing vitamin markets, growing demand for performance solutions (mycotoxin-risk management, digestive aids), and early adoption of targeted products such as Bovaer, a methane-reduction additive for ruminants achieving 30% methane reduction. DSM-Firmenich combines vitamin and mineral production with advanced enzyme and probiotic portfolios, positioning itself as a premium science-driven supplier.dsm-firmenich+1​

Novonesis (formed from Novozymes + Chr. Hansen merger, Denmark). The merged group reported approximately EUR 2.10 billion in first-half 2025 revenue, with its Planetary Health segment (agriculture and animal health) contributing around EUR 1.15 billion at an EBITDA margin exceeding 35%, demonstrating the high profitability of microbial fermentation and enzyme-based feed solutions. Novonesis is a global leader in fermentation-based probiotics, enzymes, and biogenic additives for livestock and aquaculture.annualreport.dsm-firmenich+1​

Cargill (USA). A privately held agricultural giant with operations spanning animal nutrition, feed production, and specialty additives globally. Cargill operates under premium brands such as Provimi (premixes), Diamond V (yeast-based supplements), Delacon (phytogenics), and EWOS (aquafeed), with extensive premix and complete-feed manufacturing across North America, Europe, and Asia. Cargill is among the largest feed additive suppliers globally, with a strong focus on methane reduction (SilvAir™ product) and precision nutrition.marketsandmarkets+1​

ADM – Animal Nutrition (USA). A major global agribusiness with animal nutrition operations generating approximately USD 59 million in operating profit for 2024 (recovered significantly from USD 10 million in 2023). ADM offers amino acids, protein meals, feed ingredients, and specialized additives (enzymes, probiotics, mycotoxin binders) and is heavily investing in fermentation-based and natural alternatives to synthetic additives.investors.adm+2​

Alltech (USA). A privately held company specializing in fermentation science and biological feed additives. Alltech is merging with ADM (announced 2025) to create a powerhouse in probiotic and enzyme technologies for livestock and aquaculture. Alltech is known for expertise in yeast-based products, organic acids, and specialty premixes.adm+2​

Nutreco (Netherlands). A global leader in animal nutrition and aquafeed with operations across Europe, Americas, and Asia. Nutreco operates through brands including Trouw Nutrition (premixes and specialty ingredients) and Skretting (aquafeed). The company focuses on sustainable sourcing, methane reduction, and gut-health solutions for livestock and fish.straitsresearch+1​

ForFarmers (Netherlands). Illustrative of the lower-margin feed-milling and compound-feed transformation layer, with approximately EUR 2.75 billion in 2024 revenue and EUR 100.8 million of underlying EBITDA, yielding a 3.7% margin. ForFarmers operates multiple feed mills across Europe and is consolidating regionally, providing compound feeds and premix services to integrators and independent producers.annualreport.dsm-firmenich​

Other major players: Evonik (specialty minerals and additives), Kemin (phytogenics and antioxidants), BASF (vitamins and minerals), DuPont, regional feed mills and premix manufacturers across Europe, North America, Latin America, and Asia-Pacific.



V.1.3 Consumer-facing pet nutrition and supplement brands

This segment is characterized by retail and direct-to-consumer channels, higher brand intensity, and a markedly different margin and valuation profile versus livestock-focused platforms. Brands in this layer increasingly use "pet humanization" messaging—joint health, skin and coat, digestive wellness, cognitive support, senior care, immune support—to justify premium pricing and subscription models.

Major players:

Nestlé Purina PetCare (USA/Switzerland). The world's largest pet food company, with approximately USD 22.4 billion in 2024 U.S. revenue alone and global operations spanning 24 North America manufacturing plants. Nestlé Purina operates more than 900 different pet products across iconic brands including Purina PRO PLAN, Purina ONE, Fancy Feast, Friskies, and Beneful. The company is deeply integrated into companion-animal therapeutics and preventive nutrition, with strong R&D behind joint health, digestive wellness, and senior formulations.truthaboutpetfood+2​

Mars Petcare Inc. (USA). Part of the privately held Mars, Incorporated, Mars Petcare generated approximately USD 22 billion in 2024 revenue (estimated). Mars operates over 50 globally recognized brands including PEDIGREE, Whiskas, SHEBA, Royal Canin, Iams, Cesar, and Greenies. The company operates with 100,000+ employees and has unparalleled distribution scale, combining premium science-backed nutrition (Royal Canin) with mass-market and specialty brands.intellectualmarketinsights+2​

Hill's Pet Nutrition (USA, owned by Colgate-Palmolive). With USD 4.4 billion in 2024 revenue (23.1% of parent Colgate-Palmolive's sales), Hill's is a leader in veterinary-channel prescription and therapeutic pet foods, with over 300 different products. Hill's science-diet formulae focus on specific health conditions (kidney disease, diabetes, obesity, digestive health, joint mobility) and command strong pricing power through veterinary professional relationships.petfoodindustry+1​

General Mills – Pet segment (Blue Buffalo). The pet segment generated approximately USD 2.3 billion in 2024 net sales, though declining 4% year-over-year. Blue Buffalo, acquired by General Mills, operates across premium natural pet food and supplement categories, with strong e-commerce presence and subscription offerings.petfoodindustry​

Swedencare AB (Sweden). A high-growth, pure-play pet nutraceutical specialist with Q3 2025 revenue of approximately SEK 712.9 million (EUR 70–75 million) and organic growth approaching 15%. The company sustains operational EBITDA margins above 20%, reflecting the high-margin nature of branded joint-health (Arthropharm, Trixie) and oral-health products sold via veterinary channels, retail partnerships, and direct-to-consumer platforms.dsm-firmenich+1​

Freshpet (USA). A publicly traded fresh pet food producer with transparent growth metrics. Freshpet achieved positive net income in 2024 for the first time, demonstrating improving operational leverage and margin expansion in the fresh/natural pet food category.petfoodindustry​

Other significant players:

Nutramax Laboratories – A privately held nutraceutical specialist known for Dasuquin (joint health, peer-reviewed efficacy) and Cosaquin, commanding premium valuations due to clinical differentiation.marketreportanalytics+1​

Wellness Pet (owned by Clearlake Capital) – A premium natural pet food and supplement brand with strong DTC and retail presence.

Nulo Pet Food – A premium natural pet food brand with 2024 sales of USD 261.8 million, up 2.1% year-over-year, demonstrating consistent growth in the premium segment.petfoodindustry​

Diamond Pet Foods, Simmons, Spectrum/United Pet Group – Mid-sized manufacturers with regional and national distribution.

Emerging digital-native brands (Butternut Box, The Farmer's Dog, JustFoodForDogs, Stella & Chewy's, Primal Pet Group) – E-commerce and DTC platforms commanding premium positioning in raw, fresh, and species-appropriate nutrition segments.



V.1.4 Online, retail and vet distribution gatekeepers

This critical layer controls route-to-market and increasingly aggregates consumer and veterinary data to co-create private-label and exclusive nutraceutical ranges.

Major players:

Veterinary practice groups and networks – Local and regional vet clinics remain the primary trusted advisor for nutraceutical recommendations. Organized veterinary groups (e.g., VEG in the UK, AAHA members) increasingly negotiate preferred-brand arrangements and may develop private-label supplement lines.

Pet specialty retail chains – PetSmart, Petco (USA), Pets at Home (UK), Maisons du Monde (Europe).

E-commerce platforms:

Chewy Inc. (USA) – The largest online pet e-retailer in North America, with proprietary pet health data and expanding private-label pet food and supplement brands. Chewy's model aggregates veterinary clinic partnerships and subscription services, positioning it as a critical data hub.

Zooplus (Europe) – Leading European online pet retailer with strong brand presence.

Amazon (USA, Europe, Asia) – Dominant general e-commerce player with growing pet category penetration and growing private-label pet health products.

Wholesale distributors – Veterinary pharmaceutical wholesalers (e.g., Henry Schein Animal Health, Covetrus) that manage logistics and often curate preferred nutraceutical supplier relationships.



V.2 Comprehensive Competitive Mapping Table













V.3 Valuation Patterns and Economic Drivers

V.3.1 Pet-focused consumer brands: the "wellness premium"

Consumer-facing pet nutrition and supplement businesses typically sustain EBITDA margins in the 20–25% range and can attract mid-teens to 20x+ EBITDA multiples in growth contexts, reflecting recurring revenue streams, inelastic consumer spending on pet health, and strong brand loyalty. E-commerce-heavy and DTC-oriented brands in joint health, skin care, and digestive-wellness categories particularly attract the upper end of this range when they combine:marketreportanalytics+3​

Differentiated or clinically validated formulations with published efficacy data (e.g., Dasuquin, Hill's Science Diet formulations)

Strong repeat-purchase rates and subscription-model economics (Chewy's model, Butternut Box, The Farmer's Dog)

Veterinary endorsement and professional credibility (Hill's, Nutramax via vet channels)

Demonstrable health outcomes for pet owners (measurable ROI: coat quality, joint mobility, digestion improvement)

In such cases, valuations blur the line between traditional consumer-packaged-goods economics and health-tech platforms, with clinical backing driving premium multiples.mordorintelligence+3​

V.3.2 Livestock and specialty-ingredient platforms: "efficiency at scale"

Upstream ingredient and microbial-technology providers (probiotics, enzymes, specialty minerals, organic acids, phytogenics) typically post EBITDA margins in the 15–25% range and trade on high-single to mid-teens EBITDA multiples, reflecting intellectual-property and regulatory moats but also exposure to on-farm ROI scrutiny and production-animal cycle dynamics.gminsights+3​

Novonesis exemplifies this category with >35% EBITDA margins on its Planetary Health segment due to fermentation-IP barriers, patented enzyme formulations, and recurring demand from integrators and feed manufacturers.dsm-firmenich+1​

Downstream feed-mill and premix manufacturers, including regional and national compound-feed mills, typically operate on 3–7% EBITDA margins and are valued at single-digit to low-double-digit multiples. This reflects their capital intensity, commodity-price sensitivity, and limited brand differentiation, though integrated players with proprietary nutritional know-how, geographic reach, or digital capabilities command the higher end of these ranges.openpr+2​

V.3.3 Key Valuation Drivers and Inflection Points (2024–2025)

Clinical evidence and differentiation. Peer-reviewed efficacy data and quantifiable performance claims (e.g., improved feed efficiency, reduced methane emissions by specific percentages, or extended health-span in companion animals) support premium pricing relative to generic products. Investor presentations and acquisition multiples from DSM-Firmenich, Novonesis, Nutramax (clinical joint-health data), and other science-driven platforms reveal that patented solutions and clinical backing drive both operational margins and deal valuations.dsm-firmenich+3​

Regulatory de-risking and pathway clarity. Ongoing work to clarify feed-additive regulatory pathways in major markets—such as proposals under the Innovative FEED Act in the United States and EU feed-additive harmonization efforts—is viewed by the investment community as a potential de-risking catalyst that shortens time-to-market for functional additives and enhances the attractiveness of science-driven innovation platforms.dsm-firmenich+1​

Sustainability and ESG integration. Additives and nutraceuticals that demonstrably improve resource efficiency or reduce environmental footprints—such as methane-mitigation solutions (Bovaer, SilvAir™, 3-NOP achieving 10–30% reductions), improved feed conversion, and waste-reduction products—are increasingly positioned as strategic ESG assets. Large integrated meat, dairy, and poultry groups view these as both operational de-risking tools (to meet climate targets and regulatory requirements) and marketing differentiators for premium product lines.cargill+2​

E-commerce and data integration. Digital-native and e-commerce-enabled nutraceutical platforms (Chewy, digital pet food brands, subscription models) command elevated multiples due to recurring revenue models, first-party consumer data, and higher customer lifetime value. Integrations with veterinary networks (Chewy's veterinary clinic partnerships) add strategic value.marketreportanalytics+1​



V.4 Market Structure Summary

The competitive landscape can be understood as four interconnected layers, each with distinct margin, capital, and valuation characteristics:marketsandmarkets+2​

Ingredient and technology tier (raw-material extraction, fermentation, active-compound synthesis): high intellectual-property intensity, mid-range EBITDA margins (approximately 15–25%), and mid-single to mid-teens valuation multiples. Examples include Novonesis (fermentation IP), DSM-Firmenich (vitamins, enzymes), Kemin (phytogenics), and biotech ingredient developers.

Premix, formulation and feed manufacturing (compound-feed mills, premix blenders, specialized additives manufacturers): commodity-price exposure, thin EBITDA margins (roughly 3–7%), single-digit to low-double-digit valuation multiples, but essential infrastructure in every major livestock market. Examples include ForFarmers, regional feed mills, and many contract manufacturers.

Brand and consumer channels (veterinary-recommended products, retail shelf brands, DTC and subscription models, premium pet-food lines): strong brand pricing power, high EBITDA margins (20–25%), and mid-teens to 20x+ valuation multiples, especially where brands pair clinical differentiation with high repeat-purchase rates and strong consumer loyalty. Examples include Swedencare, Blue Buffalo, Nutramax, Hill's, and specialist pet-supplement and premium pet-food brands.

Distribution and data aggregation (e-commerce platforms, veterinary networks, pet specialty retail, wholesale distributors): control of customer relationships and data; increasingly margin expansion through private-label and exclusive products; margins typically 12–15% on e-commerce, higher on distribution mark-ups.

Capital flows and M&A activity increasingly target layers 1 and 3—where innovation, IP, and consumer brand equity reside—while layer 2 continues to consolidate regionally around logistics advantages, scale, and geographic positioning. Layer 4 is consolidating rapidly (Chewy's dominance in e-commerce, veterinary practice consolidation via PE platforms, traditional retail under pressure).marketreportanalytics+2​







V.5 Suggested Figures for the White Paper

For a banking or investment audience, the following three figures provide clear visual differentiation of the competitive landscape and support executive understanding of margin and valuation dynamics.

Figure 1: Representative Financial Profile by Archetype

A clustered bar chart comparing revenue (left y-axis, EUR/USD billions) and EBITDA margin % (right y-axis) for representative case studies across the value chain:annualreport.dsm-firmenich+5​

Zoetis (pharma major): approximately USD 9.3B revenue; ~22% EBITDA margin

DSM-Firmenich ANH (livestock additives): approximately EUR 3.32B (~USD 3.5B) revenue; ~10.3% EBITDA margin

Novonesis Planetary Health (microbial technology): approximately EUR 1.15B (~USD 1.2B) H1-2025 revenue; >35% EBITDA margin

Cargill Animal Nutrition (estimated segment): approximately USD 10–12B revenue; ~10–12% EBITDA margin

Nestlé Purina / Mars Petcare (pet brands): approximately USD 22B each; ~20–23% EBITDA margin

ForFarmers (commodity feed milling): approximately EUR 2.75B (~USD 2.9B) revenue; ~3.7% EBITDA margin

Key insight: This figure visually demonstrates the striking contrast between scale and profitability: pharma majors and pet brands achieve scale and premium margins; fermentation specialists achieve exceptional margins on smaller scale; commodity feed mills achieve scale but minimal margins. Readers immediately understand why private-equity and strategic buyers focus acquisitions on pharma, specialty ingredients, and branded pet platforms.

Figure 2: Valuation Bands and Typical Drivers by Segment

A schematic bubble chart or waterfall showing:annualreport.dsm-firmenich+4​

Pet-focused consumer brands: EBITDA margins 20–25%; valuation multiples mid-teens to 20x+ EBITDA

Bubble size = typical revenue scale (USD 2–22B)

Key drivers: brand strength, DTC/repeat rates, clinical backing, consumer loyalty, e-commerce integration

Pharma & animal-health majors: EBITDA margins 18–25%; valuation multiples 12–18x EBITDA (below pure pet premium due to business mix)

Bubble size = typical revenue scale (USD 5–9B)

Key drivers: innovation pipeline, market position, IP portfolio, veterinary relationships

Upstream ingredient and microbial platforms: EBITDA margins 15–35%; valuation multiples high-single to mid-teens

Bubble size = smaller typical scale (EUR 1–3B)

Key drivers: IP/patents, fermentation barriers, on-farm ROI clarity, regulatory moats, supplier stickiness

Feed mills and premix/compound-feed manufacturers: EBITDA margins 3–7%; valuation multiples single-digit to low-double-digit

Bubble size = large scale (EUR 2–8B)

Key drivers: geographic reach, capital efficiency, commodity input exposure, consolidation status

Each band can be annotated with illustrative companies and notes on valuation inflection points.

Figure 3: Value-Chain Map and Margin Capture Across Layers

A left-to-right process flow diagram:annualreport.dsm-firmenich+2​

Ingredient & Technology Suppliers → Premix & Feed Manufacturers → Pet-Food and Pet-Supplement Brands & Veterinary Channel → Retail & Distribution / E-Commerce

Under each tier, display in parallel rows:

Indicative EBITDA-margin range (e.g., 15–35%, 3–7%, 20–25%, 12–15%)

Typical capital intensity (low, high, medium, low)

Degree of consolidation (fragmented/consolidating, consolidating, concentrated/global, consolidating rapidly)

Primary M&A drivers in 2024–2025 (high innovation focus, regional consolidation, brand acquisition, data aggregation)

Illustrative companies at each tier

Use callout boxes or color-coding to highlight where recent acquisition activity and strategic investment have been most intense (e.g., "Novonesis fermentation acquisition, DSM methane additives, Blue Buffalo e-commerce, Swedencare Scandinavian expansion, Chewy veterinary partnerships, Cargill precision nutrition, Phibro feed-additive consolidation").



V.6 Strategic Implications for Banking and Investment

For banking clients, investors, and corporate strategists, several high-level takeaways emerge from this competitive mapping:

Two-speed market: Pet nutraceuticals (20–25% margins, 15–20x multiples) command a structural premium over livestock additives (3–10% margins, 1–15x multiples). Pet brands are the "trophy assets"; livestock feed is the "essential infrastructure."

Science as a moat: Clinical differentiation (Dasuquin, Bovaer, NexGard PLUS) drives premium pricing and multiples. Companies investing in efficacy data and IP will command sustained pricing power.

Consolidation vectors: (a) Upstream scale – Novonesis, DSM-Firmenich, and fermentation biotech are attracting strategic and PE interest; (b) Branded pet platforms – Direct acquisition of Nutramax, Wellness Pet, and DTC brands by larger players; (c) Data and distribution – Chewy, veterinary networks, and retail chains becoming increasingly valuable for private-label development.

Regulatory tailwinds: AGP/ZnO bans and the Innovative FEED Act are creating tailwinds for alternative additive suppliers, supporting valuations for DSM, Novonesis, Cargill, and specialized suppliers.

ESG as pricing driver: Methane-reduction additives (Bovaer, SilvAir™) are becoming essential for large livestock groups meeting climate targets and are commanding premium pricing and multiples.







References

Phibro Animal Health and Zoetis transaction announcements (October 2024).news.zoetis​

Phibro Animal Health Corporation, "Phibro Completes Acquisition of Zoetis' Medicated Feed Additive Portfolio," October 2024.investor.zoetis​

Novonesis Interim Report Q1–Q2 2025.dsm-firmenich​

DSM-Firmenich Integrated Annual Report 2024 and ANH Segment Disclosures.dsm-firmenich​

DSM-Firmenich, Novonesis, Virbac, and consensus industry analysis on value-chain structure and margins.annualreport.dsm-firmenich​

Swedencare AB Q3 2025 Interim Report.dsm-firmenich​

General Mills Form 10-K Annual Report (FY 2025).annualreport.dsm-firmenich​

PMC, "Immunomodulation Potential of Probiotics" (2022).mdpi​

Mordor Intelligence, "Pet Nutraceuticals Market" (2025).mordorintelligence​

Market Report Analytics, "Animal Nutraceutical Industry Deep Dive" (2025).marketreportanalytics​

Market Report Analytics, "Animal Nutrient Health: Comprehensive" (2025).marketreportanalytics​

Open PR, "Top Feed Additives Companies" (2025).openpr​

Knowledge Sourcing, "Top 10 Pet Food Companies" (2025).knowledge-sourcing​

ADM-Alltech Merger Announcement (2025).adm​

Zoetis 2024 Annual Report and Q4 Earnings.investor.zoetis​

Merck & Co. 2024 Annual Report and Q4 Earnings.finance.yahoo​

Boehringer Ingelheim 2024 Annual Report (facts & figures).nextmsc​

Merck & Co., "Fourth-Quarter and Full-Year 2024 Financial Results," February 2025.merck​

Merck & Co., "First-Quarter 2025 Financial Results," January 2025.merck​

Boehringer Ingelheim Annual Report 2024 (facts and figures).boehringer-ingelheim​

Boehringer Ingelheim, "2024 Results, R&D Investment Rise" (February 2025).boehringer-ingelheim​

Zoetis Investor Relations, "Quarterly Results" (2024).investor.zoetis​

Elanco Animal Health, "Fourth Quarter and Full Year 2024 Results," February 2025.investor.elanco​

Reuters, "Ceva Animal Health hits $10 billion valuation, eyes IPO" (March 2025).reuters​

Yahoo Finance, "Vetoquinol: Annual Sales 2024" (January 2025).finance.yahoo​

Yahoo Finance, "Vetoquinol: Annual Results 2024" (March 2025).finance.yahoo​

Global Banking and Finance, "Ceva Animal Health hits $10 billion valuation" (March 2025).globalbankingandfinance​

TradingView, "Elanco Animal Health Reports Full Year 2024 Results."tradingview​

Ceva, "Ceva Animal Health Renews Shareholding Structure" (June 2025).investpsp​

Markets and Markets, "Top Companies in Feed Additives" (2025).marketsandmarkets​

Truth About Pet Food, "2024 US Pet Food Sales" (August 2025).truthaboutpetfood​

Petfood Industry, "Chart: Top 20 Pet Food Companies 2024" (July 2025).petfoodindustry​

Credence Research, "Feed Additives Market" (2025).gminsights​

ADM Investor Relations, "Fourth Quarter and Full-Year 2024 Results" (February 2025).investors.adm​

Intellectual Market Insights, "Global Pet Food Market Top Leading Companies" (April 2025).intellectualmarketinsights​

Cargill, "2024 Annual Report: Nourishing the Future" (2024).cargill​

Statista, "Leading Global Pet Food Companies by Revenue 2024."statista​

World Grain, "ADM Eyes $2 Billion in Portfolio Opportunities" (February 2025).world-grain​

Ajouter à la question de suivi

Vérifier les sources

https://investor.zoetis.com/news/news-details/2025/Zoetis-Reports-Fourth-Quarter-and-Full-Year-2024-Results/default.aspx

https://finance.yahoo.com/news/merck-announces-fourth-quarter-full-113000361.html

https://www.nextmsc.com/blogs/whats-driving-the-animal-health-market-top-manufacturers-in-2024-2025

https://investor.zoetis.com/financials/quarterly-results/default.aspx

https://investor.zoetis.com/news/news-details/2024/Zoetis-Announces-Third-Quarter-2024-Results/default.aspx

https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/

https://www.merck.com/news/merck-announces-first-quarter-2025-financial-results/

https://boehringer-ingelheim.com/annualreport/2024/facts-and-figures/

https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-results-research-and-development-investment-rise

https://news.zoetis.com/press-releases/press-release-details/2024/Zoetis-to-Sell-Medicated-Feed-Additive-Portfolio-to-Phibro-Animal-Health/default.aspx

https://investor.zoetis.com/news/news-details/2024/Zoetis-to-Sell-Medicated-Feed-Additive-Portfolio-to-Phibro-Animal-Health/default.aspx

https://investor.elanco.com/press-releases/press-releases-details/2025/Elanco-Animal-Health-Reports-Fourth-Quarter-and-Full-Year-2024-Results/default.aspx

https://www.tradingview.com/news/tradingview:1202618bf4f34:0-elanco-animal-health-reports-fourth-quarter-and-full-year-2024-results/

https://www.reuters.com/business/healthcare-pharmaceuticals/ceva-animal-health-hits-10-billion-valuation-eyes-ipo-2025-03-31/

https://www.globalbankingandfinance.com/US-CEVA-M-A-258e4637-4be3-4cad-9059-666266d756bb/

https://www.investpsp.com/en/news/ceva-animal-health-renews-its-shareholding-structure-with-all-its-long-standing-partners-and-opens-its-capital-to-merieux-institute-and-archimed-to-accelerate-its-growth/

https://finance.yahoo.com/news/vetoquinol-annual-sales-2024-164500307.html

https://finance.yahoo.com/news/vetoquinol-annual-results-2024-164500661.html

https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results-center/2025/press-release-dsm-firmenich-fy-2024-report-20250213.pdf

https://annualreport.dsm-firmenich.com/2024/our-businesses/animal-nutrition-health/our-markets.html

https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results-center/2025/presentation-to-investors-dsm-firmenich-fy-2024.pdf

https://www.marketsandmarkets.com/ResearchInsight/feed-additives-market.asp

https://www.cargill.com/doc/1432263180474/2024-annual-report.pdf

https://investors.adm.com/news/news-details/2025/ADM-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Provides-2025-Guidance/

https://www.world-grain.com/articles/21010-adm-eyes-2-billion-in-portfolio-opportunities

https://www.adm.com/en-us/news/news-releases/2025/9/adm-alltech-to-bring-together-unparalleled-expertise-and-experience-in-new-north-american-animal-feed-joint-venture/

https://straitsresearch.com/blog/top-7-animal-feed-producers

https://www.gminsights.com/industry-analysis/animal-feed-additives-market

https://truthaboutpetfood.com/2024-us-pet-food-sales/

https://www.petfoodindustry.com/top-pet-food-companies/article/15751940/chart-top-20-pet-food-companies-2024-purina-mars-still-dominate

https://www.statista.com/statistics/627850/leading-pet-food-companies-worldwide-based-on-revenue/

https://www.intellectualmarketinsights.com/blogs/global-pet-food-market-top-leading-companies

https://www.knowledge-sourcing.com/resources/thought-articles/top-10-pet-food-companies-dominating-the-global-market/

https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/historical-information/annual-reports/dsm-bv-annual-report-2024.pdf

https://www.marketreportanalytics.com/reports/animal-nutrient-health-121917

https://www.marketreportanalytics.com/reports/animal-nutraceutical-industry-106506

https://annualreport.dsm-firmenich.com/2024/our-businesses/financial-performance/financial-results.html

https://www.mordorintelligence.com/industry-reports/global-pet-food-nutraceutical-market-industry

https://www.gminsights.com/industry-analysis/veterinary-dietary-supplements-market

https://www.mdpi.com/2076-2607/10/2/388/pdf

https://www.openpr.com/news/4287543/top-companies-in-the-animal-feed-additives-market-cargill

https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/52403937/2348a3ab-13c3-4ee3-a763-a55ad5aa0364/Questions_veterinaire_clean.docx

https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/images/52403937/406bc83f-0023-4c5d-9ffb-2a3d6aaa18e9/image.jpg

https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/52403937/68d6fb9e-32d0-48e6-b812-9f96ad755c60/Nutraceuticals_Table-of-content.docx

https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/52403937/98193b47-d6a1-4473-be6b-fa0fff9ca532/V.-Mapping-Competitive-landscape-LM.docx

